Compared to patients with normal vitamin D levels, patients with vitamin D deficiency were considered more than twice as likely to have diabetes, 29% more likely to have cardiomyopathy, and 40% more likely to have high blood pressure.
Vitamin D supplementation could significantly improve heart health in vitamin D deficient patients, according to a U.S. cohort study published in The American Journal of Cardiology.
Researchers at the University of Kansas tested serum vitamin D levels in 10,899 patients, 71% of whom were women and 70.3% of whom were vitamin D deficient.
Compared to patients with normal vitamin D levels, patients with vitamin D deficiency were considered more than twice as likely to have diabetes, 29% more likely to have cardiomyopathy, and 40% more likely to have high blood pressure. Furthermore, patients with vitamin D deficiency were more than three times as likely to die from all-cause death during the study.
Independent of cardio-protective drug use, patients who took vitamin D supplements saw better survival rates. These patients were 60% less likely to die from any cause during the study-a benefit deemed significant only in patients who initially tested as vitamin D deficient.
“Our study suggests a significant association of vitamin D supplement use and improved survival in deficient subjects, supporting the potential benefit of this intervention,” wrote the study’s lead researcher.
While the study supports gaining research on vitamin D and a potential benefit for heart health, some limitations were noted. Use of multivitamins was not considered as vitamin D supplementation and dose and duration of vitamin D supplementation were not analyzed.
Sirio Pharma launches line of ready-to-market organic gummies and softgels called PureOrganix
August 26th 2024The new line is made up of three gummies and one softgel that are formulated to meet stringent EU-Organic certification criteria, and target women’s health, metabolic health, and heart health.
SourceOne Global Partners to distribute Qualitas Health’s microalgae omega-3 ingredient globally
August 15th 2024SourceOne Global Partners has announced a partnership with Qualitas Health Inc., (dba iwi life) to introduce the company’s trademarked AlmegaPL microalgae omega-3 ingredient to the global marketplace.
Meta-analysis does not find increased risk of bleeding events from omega-3 PUFA consumption
July 8th 2024Researchers reviewed 11 studies and found that there was no difference in the incidence of bleeding events between patients receiving omega-3 PUFAs and those not receiving them. High dose EPA consumption was associated with an elevated but modest risk.